STOCK TITAN

Evolus to Participate in the Barclays Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the Barclays Global Healthcare Conference in Miami Beach, Florida.

Event:

 

Barclays Global Healthcare Conference

Date:

 

Tuesday, March 14, 2023

Time:

 

2:35-3:00pm ET

An audio webcast of this event will be available on the investor relations section of Evolus’ website at www.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Visit us at www.evolus.com and follow us on LinkedIn, Twitter, Instagram or Facebook.

Jeuveau® is a registered trademark of Evolus, Inc.
Hi-Pure is a trademark of Daewoong Pharmaceutical Co, Ltd.

Investor/Media Contact:

David K. Erickson, Evolus, Inc.

Vice President, Investor Relations

Tel: 949-966-1798

Email: david.erickson@evolus.com

Media Contact:

Email: media@evolus.com

Source: Evolus

Evolus Inc

NASDAQ:EOLS

EOLS Rankings

EOLS Latest News

EOLS Stock Data

Medicinal and Botanical Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
US
Newport Beach

About EOLS

evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.